Leerink Resumes Genmab A/S (GMAB) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GMAB Hot Sheet
Price: $43.79 +9.48%
Rating Summary:
12 Buy, 2 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 16
Rating Summary:
12 Buy, 2 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 16
Join SI Premium – FREE
Leerink analyst Asthika Goonewardene resumes coverage on Genmab A/S (NASDAQ: GMAB) with a Outperform rating and a price target of $50.00.
For an analyst ratings summary and ratings history on Genmab A/S click here. For more ratings news on Genmab A/S click here.
Shares of Genmab A/S closed at $34.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citizens Starts Oaktree Specialty Lending Corp (OCSL) at Market Perform
- Citizens Starts Blackstone Secured Lending Fund (BXSL) at Market Perform
- Stifel Starts Powerlaw Corp (PWRL) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
